ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Psychiatry · Eur Psychiatry · 2026-04-21

Secondary analysis of EULAST in 492 patients with early-phase schizophrenia: EQ-5D-5L quality of life improved over up to 19 months with no significant difference between long-acting injectable and oral antipsychotics, or between aripiprazole and paliperidone.

Secondary analysisn = 492
Schulze et al. Quality of life in early-phase schizophrenia patients starting treatment with long-acting injectable vs. oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)
Psychiatry · J Affect Disord · 2026-04-14

Network meta-analysis of 44 RCTs (10 867 participants) of bipolar disorder maintenance: in sensitivity analysis, several drugs and doses, including lithium 800 mg/day, quetiapine, aripiprazole, asenapine, lurasidone and olanzapine, outperformed placebo.

Meta-analysisn = 10,867
Fornaro et al. Efficacy and safety of pharmacological interventions for the maintenance of bipolar disorder: A systematic review and dose-related network meta-analysis across different age groups

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.